Diperflox may be available in the countries listed below.
Norfloxacin pivaloyloxymethyl ester (a derivative of Norfloxacin) is reported as an ingredient of Diperflox in the following countries:
International Drug Name Search
Definition of Ovarian Cancer: Ovarian cancer is a malignant neoplasm (abnormal growth) located on the ovaries.
The following drugs and medications are in some way related to, or used in the treatment of Ovarian Cancer. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Micromedex Care Notes:
Medical Encyclopedia:
Harvard Health Guide:
Veterinary Injection For Intramuscular Use in Cats
and Subhuman Primates Only
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
KETASET (ketamine hydrochloride injection, USP) is a rapid-acting, nonnarcotic, nonbarbiturate agent for anesthetic use in cats and for restraint in subhuman primates. It is chemically designated dl 2-(o-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and is supplied as a slightly acid (pH 3.5 to 5.5) solution for intramuscular injection in a concentration containing the equivalent of 100 mg ketamine base per milliliter and contains not more than 0.1 mg/mL benzethonium chloride as a preservative.
KETASET is a rapid-acting agent whose pharmacological action is characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, mild cardiac stimulation and respiratory depression. Skeletal muscle tone is variable and may be normal, enhanced or diminished. The anesthetic state produced does not fit into the conventional classification of stages of anesthesia, but instead KETASET produces a state of unconsciousness which has been termed "dissociative" anesthesia in that it appears to selectively interrupt association pathways to the brain before producing somesthetic sensory blockade.
In contrast to other anesthetics, protective reflexes, such as coughing and swallowing are maintained under KETASET anesthesia. The degree of muscle tone is dependent upon level of dose; therefore, variations in body temperature may occur. At low dosage levels there may be an increase in muscle tone and a concomitant slight increase in body temperature. However, at high dosage levels there is some diminution in muscle tone and a resultant decrease in body temperature, to the point where supplemental heat may be advisable.
In cats, there is usually some transient cardiovascular stimulation, increased cardiac output with slight increase in mean systolic pressure with little or no change in total peripheral resistance. At higher doses the respiratory rate is usually decreased.
The assurance of a patent airway is greatly enhanced by virtue of maintained pharyngeal-laryngeal reflexes. Although some salivation is occasionally noted, the persistence of the swallowing reflex aids in minimizing the hazards associated with ptyalism. Salivation may be effectively controlled with atropine sulfate in dosages of 0.04 mg/kg (0.02 mg/lb) in cats and 0.01 to 0.05 mg/kg (0.005 to 0.025 mg/lb) in subhuman primates.
Other reflexes, e.g., corneal, pedal, etc., are maintained during KETASET anesthesia, and should not be used as criteria for judging depth of anesthesia. The eyes normally remain open with the pupils dilated. It is suggested that a bland ophthalmic ointment be applied to the cornea if anesthesia is to be prolonged.
Following administration of recommended doses, cats become ataxic in about 5 minutes with anesthesia usually lasting from 30 to 45 minutes at higher doses. At the lower doses, complete recovery usually occurs in 4 to 5 hours but with higher doses recovery time is more prolonged and may be as long as 24 hours.
In studies involving 14 species of subhuman primates represented by at least 10 anesthetic episodes for each species, the median time to restraint ranged from 1.5 [Aotus trivirgatus (night monkey) and Cebus capucinus (white-throated capuchin)] to 5.3 minutes [Macaca nemestrina (pig-tailed macaque)]. The median duration of restraint ranged between 20 and 55 minutes in all but five of the species studied. Total time from injection to end of restraint ranged from 43 [Saimiri sciureus (squirrel monkey)] to 183 minutes [Macaca nemestrina (pig-tailed macaque)] after injection. Recovery is generally smooth and uneventful. The duration is dose related.
By single intramuscular injection, KETASET usually has a wide margin of safety in cats and subhuman primates. In cats, cases of prolonged recovery and death have been reported.
KETASET may be used in cats for restraint or as the sole anesthetic agent for diagnostic or minor, brief, surgical procedures that do not require skeletal muscle relaxation. It may be used in subhuman primates for restraint.
KETASET is contraindicated in cats and subhuman primates suffering from renal or hepatic insufficiency.
KETASET is detoxified by the liver and excreted by the kidneys; therefore, any preexistent hepatic or renal pathology or impairment of function can be expected to result in prolonged anesthesia; related fatalities have been reported.
In cats, doses in excess of 50 mg/kg during any single procedure should not be used. The maximum recommended dose in subhuman primates is 40 mg/kg.
To reduce the incidence of emergence reactions, animals should not be stimulated by sound or handling during the recovery period. However, this does not preclude the monitoring of vital signs.
Apnea, respiratory arrest, cardiac arrest and death have occasionally been reported with ketamine used alone, and more frequently when used in conjunction with sedatives or other anesthetics. Close monitoring of patients is strongly advised during induction, maintenance and recovery from anesthesia.
Color of solution may vary from colorless to very slightly yellowish and may darken upon prolonged exposure to light. This darkening does not affect potency. Do not use if precipitate appears.
Respiratory depression may occur following administration of high doses of KETASET (ketamine hydrochloride injection, USP). If at any time respiration becomes excessively depressed and the animal becomes cyanotic, resuscitative measures should be instituted promptly. Adequate pulmonary ventilation using either oxygen or room air is recommended as a resuscitative measure.
Adverse reactions reported have included emesis, salivation, vocalization, erratic recovery and prolonged recovery, spastic jerking movements, convulsions, muscular tremors, hypertonicity, opisthotonos, dyspnea and cardiac arrest. In the cat, myoclonic jerking and/or mild tonic convulsions can be controlled by ultrashortacting barbiturates which should be given to effect. The barbiturates should be administered intravenously at a dose level of one-sixth to one-fourth the usual dose for the product being used. Acepromazine may also be used. However, recent information indicates that some phenothiazine derivatives may potentiate the toxic effects of organic phosphate compounds such as found in flea collars and certain anthelmintics. A study has indicated that ketamine hydrochloride alone does not potentiate the toxic effects of organic phosphate compounds.
KETASET is well tolerated by cats and subhuman primates when administered by intramuscular injection.
Fasting prior to induction of anesthesia or restraint with KETASET is not essential; however, when preparing for elective surgery, it is advisable to withhold food for at least six hours prior to administration of KETASET.
Anesthesia may be of shorter duration in immature cats. Restraint in subhuman primate neonates (less than 24 hours of age) is difficult to achieve.
As with other anesthetic agents, the individual response to KETASET is somewhat varied depending upon the dose, general condition and age of the subject so that dosage recommendations cannot be absolutely fixed.
A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint. Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.
The recommended restraint dosages of KETASET for the following species are: Cercocebus torquatus (white-collared mangabey), Papio cynocephalus (yellow baboon), Pantroglodytes verus (chimpanzee), Papio anubis (olive baboon), Pongo pygmaeus (orangutan), Macaca nemestrina (pigtailed macaque) 5 to 7.5 mg/kg; Presbytis entellus (entellus langur) 3 to 5 mg/kg; Gorilla gorilla gorilla (gorilla) 7 to 10 mg/kg; Aotus trivirgatus (night monkey) 10 to 12 mg/kg; Macaca mulatta (rhesus monkey) 5 to 10 mg/kg; Cebus capucinus (white-throated capuchin) 13 to 15 mg/kg; and Macaca fascicularis (crab-eating macaque), Macaca radiata (bonnet macaque) and Saimiri sciureus (squirrel monkey) 12 to 15 mg/kg.
A single intramuscular injection produces restraint suitable for TB testing; radiography, physical examination or blood collection.
Store at or below 25°C (77°F). Protect from light.
KETASET (ketamine hydrochloride injection, USP) is supplied as the hydrochloride in concentrations equivalent to ketamine base.
Each 10 mL vial contains 100 mg/mL.
NDC 0856-2013-01 — 10 mL — vial
KETASET has been clinically studied in subhuman primates in addition to those species listed under Administration and Dosage. Dosages for restraint in these additional species, based on limited clinical data, are: Cercopithecus aethiops (grivet), Papio papio (guinea baboon) 10 to 12 mg/kg; Erythrocebus patas patas (patas monkey) 3 to 5 mg/kg; Hylobates lar (white-handed gibbon) 5 to 10 mg/kg; Lemur catta (ringtailed lemur) 7.5 to 10 mg/kg; Macaca fuscata (Japanese macaque) 5 mg/kg; Macaca speciosa (stumptailed macaque) and Miopithecus talapoin (mangrove monkey) 5 to 7.5 mg/kg; and Symphalangus syndactylus (siamangs) 5 to 7 mg/kg.
Fort Dodge Animal Health
Fort Dodge, Iowa 50501 USA
01109
Rev. April 2009
4409C
NADA 45-290, Approved by FDA
NDC 0856-2013-01
Ketaset® CIII
KETAMINE HCl
INJECTION, USP
FORT DODGE®
Equivalent to
1000 mg/10 mL
(100 mg/mL)
Ketamine
CAUTION: Federal law restricts
this drug to use by or on the
order of a licensed veterinarian.
NADA 45-290
Approved by FDA
| KETASET ketamine hydrochloride injection | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NADA | NADA045290 | 12/23/1970 | |
| Labeler - FDAH, Division of Wyeth (149957656) |
| Registrant - Pfizer Inc. (001326495) |
Definition of Osteoporosis: Osteoporosis is the thinning of bone tissue and loss of bone density over time.
The following drugs and medications are in some way related to, or used in the treatment of Osteoporosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
See sub-topics
Micromedex Care Notes:
Medical Encyclopedia:
Harvard Health Guide:
Vitamina A may be available in the countries listed below.
Betacarotene is reported as an ingredient of Vitamina A in the following countries:
Retinol acetate (a derivative of Retinol) is reported as an ingredient of Vitamina A in the following countries:
Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Vitamina A in the following countries:
International Drug Name Search
Definition of Oppositional Defiant Disorder: Oppositional defiant disorder is a pattern of disobedient, hostile, and defiant behavior toward authority figures.
The following drugs and medications are in some way related to, or used in the treatment of Oppositional Defiant Disorder. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
Bosoptin may be available in the countries listed below.
Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Bosoptin in the following countries:
International Drug Name Search
Pantocid may be available in the countries listed below.
Pantoprazole is reported as an ingredient of Pantocid in the following countries:
Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantocid in the following countries:
International Drug Name Search
Definition of Oliguria:
Secretion of a diminished amount of urine in relation to the fluid intake.
Synonym: hypouresis, oligouresis.
The following drugs and medications are in some way related to, or used in the treatment of Oliguria. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Lomequin may be available in the countries listed below.
Lomefloxacin hydrochloride (a derivative of Lomefloxacin) is reported as an ingredient of Lomequin in the following countries:
International Drug Name Search
MOXIVIG
1 ml of solution contains 5.45 mg moxifloxacin hydrochloride equivalent to 5 mg moxifloxacin base.
Each eye drop contains 190 micrograms of moxifloxacin.
For a full list of excipients, see section 6.1.
Eye drops (solution)
Clear, greenish
Topical treatment of purulent bacterial conjunctivitis, caused by moxifloxacin susceptible strains (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Ocular use
Use in adults including the elderly
The dose is one drop in the affected eye(s) 3 times a day.
The infection normally improves within 5 days and treatment should then be continued for a further 2
Paediatric patients
No dosage adjustment is necessary.
Use in hepatic and renal impairment
No dosage adjustment is necessary.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
In order to prevent the drops from being absorbed via the nasal mucosa, particularly in new-born infants or children, the nasolacrimal ducts should be held closed for 2 to 3 minutes with the fingers after administering the drops.
If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart.
Hypersensitivity to the active substance, to any of the excipients, or to other quinolones
In patients receiving systemically administered quinolones, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial oedema), airway obstruction, dyspnoea, urticaria, and itching.
If an allergic reaction to MOXIVIG occurs, discontinue use of the medicinal product. Serious acute hypersensitivity reactions to moxifloxacin or any other product ingredient may require immediate emergency treatment. Oxygen and airway management should be administered where clinically indicated.
As with other anti
Data are very limited to establish efficacy and safety of MOXIVIG in the treatment of conjunctivitis in neonates. Therefore use of this medicinal product to treat conjunctivitis in neonates is not recommended.
MOXIVIG should not be used for the prophylaxis or empiric treatment of gonococcal conjunctivitis, including gonococcal ophthalmia neonatorum, because of the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae. Patients with eye infections caused by Neisseria gonorrhoeae should receive appropriate systemic treatment.
The medicinal product is not recommended for the treatment of Chlamydia trachomatis in patients less than 2 years of age as it has not been evaluated in such patients. Patients older than 2 years of age with eye infections caused by Chlamydia trachomitis should receive appropriate systemic treatment.
Neonates with ophthalmia neonatorum should receive appropriate treatment for their condition, e.g. systemic treatment in cases caused by Chlamydia trachomitis or Neisseria gonorrhoeae.
Patients should be advised not to wear contact lenses if they have signs and symptoms of a bacterial ocular infection.
No specific interaction studies have been performed with MOXIVIG 0.5%w/v Eye Drops, Solution. Given the low systemic concentration of moxifloxacin following topical ocular administration of the medicinal product (see Section 5.2), drug interactions are unlikely to occur.
Pregnancy
There are no adequate data from the use of MOXIVIG in pregnant women. However, no effects on pregnancy are anticipated since the systemic exposure to moxifloxacin is negligible. The medicinal product can be used during pregnancy.
Lactation
It is unknown whether moxifloxacin is excreted in human breast milk. Animal studies have shown excretion of low levels in breast milk after oral administration of moxifloxacin. However, at therapeutic doses of MOXIVIG no effects on the suckling child are anticipated. The medicinal product can be used during breast-feeding.
As with any eye drops, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient should wait until their vision clears before driving or using machinery.
In clinical studies involving 1,740 patients, MOXIVIG was administered up to 8 times a day, with 1,452 of these patients receiving treatment 3 times daily. The overall safety population that received the medicinal product consisted of 877 patients from the United States and Canada, 586 patients from Japan and 277 patients from India. No serious ophthalmic or systemic undesirable effects related to the medicinal product were reported in any of the clinical studies. The most frequently reported treatment-related undesirable effects with the medicinal product were eye irritation and eye pain, occurring at an overall incidence of 1 to 2%. These reactions were mild in 97% of those patients who experienced them, with only 1 patient discontinuing therapy as a result.
The following undesirable effects were assessed to be treatment-related and are classified according to the following convention: very common (
Blood and lymphatic system disorders
Uncommon: haemoglobin decreased
Nervous system disorders
Common: dysgeusia
Uncommon: headache, paraesthesia
Eye disorders
Common: eye pain, eye irritation, dry eye, eye pruritus, conjunctival hyperaemia, ocular hyperaemia
Uncommon: corneal epithelium defect, punctate keratitis, corneal staining, conjunctival haemorrhage, conjunctivitis, eye swelling, ocular discomfort, vision blurred, visual acuity reduced, eyelid disorder, erythaema of eyelid, abnormal sensation in eye
Respiratory, thoracic, and mediastinal disorders
Uncommon: nasal discomfort, pharyngolaryngeal pain, sensation of foreign body (throat)
Gastrointestinal disorders
Uncommon: vomiting
Hepatobiliary disorders
Uncommon: alanine aminotransferase increased, gamma-glutamyltransferase increased
Adverse reactions identified from post-marketing experience that have not been reported previously in clinical trials with the medicinal product include the following. The frequency category in which these adverse reactions occur is not known and cannot be estimated from the available data.
Cardiac disorders:
Not known: palpitations
Nervous system disorders:
Not known: dizziness
Eye disorders:
Not known: endophthalmitis, ulcerative keratitis, corneal erosion, corneal abrasion, intraocular pressure increased, corneal opacity, corneal infiltrates, corneal deposits, eye allergy, keratitis, corneal oedema, photophobia, corneal disorder, blepharitis, eyelid oedema, lacrimation increased, eye discharge, foreign body sensation in eyes
Respiratory, thoracic, and mediastinal disorders:
Not known: dyspneoa
Gastrointestinal disorders:
Not known: nausea
Skin and subcutaneous tissue disorders:
Not known: erythema, rash, pruritus
Immune system disorders:
Not known: hypersensitivity
Paediatric population
Based on data from clinical trials involving paediatric patients, including neonates (see section 5.1), the type and severity of adverse reactions in the paediatric population are similar to those in adults
No case of overdose with MOXIVIG has been reported. The limited holding capacity of the conjunctival sac for ophthalmic products practically precludes any overdosing of the medicinal product.
The total amount of moxifloxacin in a single container is too small to induce adverse effects after accidental ingestion.
Pharmacotherapeutic group: Ophthalmologicals; anti
Mode of Action:
Moxifloxacin, a fourth-generation fluoroquinolone, inhibits the DNA gyrase and topoisomerase IV required for bacterial DNA replication, repair, and recombination.
Mechanisms of Resistance:
Resistance to fluoroquinolones, including moxifloxacin, occurs generally by chromosomal mutations in genes encoding DNA gyrase and topoisomerase IV. In Gram-negative bacteria, moxifloxacin resistance can be due to mutations in mar (multiple antibiotic resistance) and the qnr (quinolone resistance) gene systems. Cross-resistance with beta-lactams, macrolides and aminoglycosides is not expected due to differences in mode of action.
Breakpoints
The minimal inhibitory concentration (MIC) breakpoints (mg/l) established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
|
|
The in vitro breakpoints have been useful in predicting clinical efficacy of moxifloxacin when administered systemically. These breakpoints might not be applicable on topical ocular use of the medicinal product as higher concentrations are obtained in the eye and the local physical/chemical circumstances can influence the activity of the product on the site of administration.
Susceptibility:
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of moxifloxacin in at least some types of infections is questionable.
|
|
|
|
|
|
Following topical ocular administration of MOXIVIG, moxifloxacin was absorbed into the systemic circulation. Plasma concentrations of moxifloxacin were measured in 21 male and female subjects who received bilateral topical ocular doses of the medicinal product 3 times a day for 4 days. The mean steadymax and AUC were 2.7 ng/ml and 41.9 ng·hr/ml, respectively. These exposure values are approximately 1,600 and 1,200 times lower than the mean Cmax and AUC reported after therapeutic 400 mg oral doses of moxifloxacin. The plasma half
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure following administration to the eye indicating little relevance to clinical use.
As with other quinolones, moxifloxacin was also genotoxic in vitro in bacteria and mammalian cells. As these effects can be traced to the interaction with bacterial gyrase and in considerably higher concentrations to the interaction with topoisomerase II in mammalian cells, a threshold level for genotoxicity can be assumed. In in vivo tests, no evidence of genotoxicity was found, despite high doses of moxifloxacin. The therapeutic doses for human use therefore provide adequate safety margin. No indication of a carcinogenic effect was observed in an initiation promotion model in rats.
Unlike other quinolones, moxifloxacin showed no phototoxic or photogenotoxic properties in extensive in vitro and in vivo studies.
Sodium chloride
Boric acid
Hydrochloric acid and/or sodium hydroxide (to adjust pH)
Purified water
Not applicable
3 years
Discard 4 weeks after first opening.
This medicinal product does not require any special storage conditions.
5 ml bottle with DROP
Pack size: box containing 1 bottle
Any unused product or waste material should be disposed of in accordance with local requirements.
Alcon Laboratories (UK) Ltd
Pentagon Park
Boundary Way
Hemel Hempstead
Herts
HP2 7UD
United Kingdom
PL 00649/0378
27/07/2009
31/03/2010
Liondox may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Liondox in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Ulcerative Proctitis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The following drugs and medications are in some way related to, or used in the treatment of Uterine Bleeding. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Generic Name: coagulation factor VIIa (injection) (koe AG yoo LAY shun FAK tor)
Brand Names: NovoSeven, NovoSeven RT
Coagulation factor VIIa is a man-made protein that is similar to a natural protein in the body that helps the blood to clot.
Coagulation factor VIIa is used to treat or prevent bleeding in people with hemophilia A or hemophilia B, or factor VII deficiency.
Coagulation factor VIIa may also be used for other purposes not listed in this medication guide.
Before using this medication, tell your doctor if you are allergic to any drugs, or if you have coronary artery disease (hardening of the arteries), a history of stroke or heart attack, a severe injury or infection, or if you are allergic to mouse, hamster, or pork proteins.
To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.
If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before using coagulation factor VIIa, tell your doctor if you have:
coronary artery disease (hardening of the arteries);
a history of stroke or heart attack;
a severe injury or infection; or
if you are allergic to mouse, hamster, or pork proteins.
Coagulation factor VIIa is given as an injection through a needle placed into a vein. Your doctor, nurse, or other healthcare provider will give you this injection. You may be shown how to use your medicine at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of needles, IV tubing, and other items used in giving the medicine.
You may need to mix coagulation factor VIIa with a liquid (diluent) before using it. If you are using the injections at home, be sure you understand how to properly mix and store the medication. Do not use the medication if it has changed colors or has any particles in it. Call your doctor for a new prescription.
To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.
After mixing NovoSeven RT with a diluent, you may keep it at room temperature or in the refrigerator and use it within 3 hours. Do not freeze or store the mixture in a syringe.
Contact your doctor if you miss a dose of this medication.
An overdose of coagulation factor VIIa is not expected to produce life-threatening symptoms.
Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using this medication.
fever;
any bleeding that will not stop;
feeling like you might pass out;
urinating less than usual or not at all;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance; or
pain or swelling in one or both legs.
Less serious side effects may include:
headache;
joint pain;
nausea, vomiting;
swelling;
mild itching or rash; or
pain, redness, swelling, or irritation where the medicine was injected.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially medications used to treat severe bleeding episodes, such as:
aminocaproic acid (Amicar); or
tranexamic acid (Cyklokapron).
This list is not complete and there may be other drugs that can interact with coagulation factor VIIa. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: NovoSeven side effects (in more detail)
Cloxacillin-Benzathin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cloxacillin benzathine (a derivative of Cloxacillin) is reported as an ingredient of Cloxacillin-Benzathin in the following countries:
International Drug Name Search
Definition of Behcet's Disease:
Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, although there have been reports of a virus found in some individuals with the disease. Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement.
The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in Japan, Turkey and Israel, and less common in the United States.
The following drugs and medications are in some way related to, or used in the treatment of Behcet's Disease. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Harvard Health Guide:
Definition of Blastomycosis: Blastomycosis is a rare fungal infection caused by inhaling a fungus ( More...
The following drugs and medications are in some way related to, or used in the treatment of Blastomycosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
The following drugs and medications are in some way related to, or used in the treatment of Bronchospasm Prophylaxis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
The following drugs and medications are in some way related to, or used in the treatment of Barium Meal Transit. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The following drugs and medications are in some way related to, or used in the treatment of Bone Marrow Transplantation, Myeloid Reconstruction. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
Treating cytomegalovirus (CMV) eye infection in patients with AIDS.
Vitrasert Implant is an antiviral agent. It works by blocking the ability of the virus to replicate, which slows the progression of the infection.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Vitrasert Implant. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Vitrasert Implant. Because little, if any, of Vitrasert Implant is absorbed into the blood, the risk of it interacting with another medicine is low.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Vitrasert Implant may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Vitrasert Implant as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Vitrasert Implant.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Increased pressure in the eye.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bleeding in the eye; change in vision or loss of vision; decrease in vision; pain, redness, or light sensitivity in the treated eye; seeing flashes or floating spots.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Vitrasert side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Vitrasert Implant is usually handled and stored by a health care provider. If you are using Vitrasert Implant at home, store Vitrasert Implant as directed by your pharmacist or health care provider. Keep Vitrasert Implant out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Vitrasert Implant. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: clotrimazole (Topical route)
kloe-TRIM-a-zole
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Antifungal
Chemical Class: Imidazole
Clotrimazole topical preparations are used to treat fungus infections on the skin.
This medicine is available both over-the-counter (OTC) and with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
This medicine has been tested in children and, in effective doses, has not been shown to cause different side effects or problems than it does in adults.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of topical clotrimazole in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
This section provides information on the proper use of a number of products that contain clotrimazole. It may not be specific to Mycelex. Please read with care.
Apply enough clotrimazole to cover the affected and surrounding skin areas, and rub in gently.
Keep this medicine away from the eyes.
When clotrimazole is used to treat certain types of fungus infections of the skin, an occlusive dressing (airtight covering, such as kitchen plastic wrap) should not be applied over the medicine. To do so may cause irritation of the skin. Do not apply an occlusive dressing over this medicine unless you have been directed to do so by your doctor.
To help clear up your infection completely, it is very important that you keep using this medicine for the full time of treatment , even if your symptoms begin to clear up after a few days. Since fungus infections may be very slow to clear up, you may have to continue using this medicine every day for several weeks or more. If you stop using this medicine too soon, your symptoms may return. Do not miss any doses .
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
If your skin problem does not improve within 4 weeks, or if it becomes worse, check with your doctor.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Mycelex Topical side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Treating acne. It may also be used for other conditions as determined by your doctor.
Adapalene Solution is a retinoid-like medicine. It works by decreasing acne formation.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Adapalene Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Adapalene Solution. Because little, if any, of Adapalene Solution is absorbed into the blood, the risk of it interacting with another medicine is low.
Ask your health care provider if Adapalene Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Adapalene Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Adapalene Solution.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Acne; dry skin; feeling of warmth; irritation; itching; peeling; redness; scaling; sunburn; temporary burning or stinging.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blistering; crusting; excessive redness or peeling; swelling.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Adapalene side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Adapalene Solution at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Keep bottle tightly closed and store upright. Do not store in the bathroom. Keep Adapalene Solution out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Adapalene Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Sevofluran Baxter may be available in the countries listed below.
Sevoflurane is reported as an ingredient of Sevofluran Baxter in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Neutropenia Associated with AIDS or Zidovudine. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
